I don't understand this. If it's the same drug for both trials, why would you partner for one and not the other. I doubt manufacture or end sales would be allocated to one condition and not the other.
Ann: Quarterly Appendix 4C and Activities Report, page-213
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $335.3M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18064 | 61.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 59.0¢ | 4000 | 1 |
View Market Depth
| Last trade - 09.38am 21/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |
Day chart unavailable